Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Nov. 30, 2018
Nov. 30, 2017
Cash flows from operating activities:    
Net (loss) income $ (854,824) $ 2,315,100
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Depreciation and amortization expense 317,326 229,995
Loss on disposal of property and equipment 162,307  
Change in fair value of contingent consideration (415,280)  
Compensatory element of stock options 478,378 971,730
Provision for doubtful accounts 727,483 77,012
Deferred income tax expense 2,378,491 (774,806)
Amortization of debt issuance costs 109,292 125,434
Changes in assets and liabilities:    
Accounts receivable (1,347,773) (1,149,875)
Prepaid expenses (20,796) 23,349
Inventory 316,650 46,576
Other current assets (48,329) (127,688)
Goodwill 66,565  
Deposits and other assets, net (85,000) (3,388)
Accounts payable (666,889) 443,112
Accrued expenses 120,313 28,145
Deferred revenue 4,095,416 3,513,477
Net provided by operating activities 5,333,330 5,718,173
Cash flows used in investing activities (net of effect of business combination):    
Purchases of property and equipment (446,163) (98,333)
Purchase of intangible asset (200,000)  
(Purchases) sales of marketable securities and other investments, net (136,248) 191,358
Net cash (used in) provided by investing activities (11,282,411) 93,025
Cash flows from financing activities (net of effect of business combination):    
Treasury stock purchases   (446,621)
Repayments of note payable (3,291,665) (2,650,000)
Proceeds from the exercise of stock options 170,925 64,696
Proceeds from note payable 9,000,000  
Issuance costs associated with the proceeds from the note payable (169,300)  
Net cash provided by (used in) financing activities 5,709,960 (3,031,925)
(Decrease) Increase in cash and cash equivalents (239,121) 2,779,273
Cash and cash equivalents - beginning of period 6,279,154 3,499,881
Cash and cash equivalents - end of period 6,040,033 6,279,154
Supplemental non-cash investing activities:    
Unrealized gain on marketable securities, net of tax 300,119 $ 6,457
Assets acquired and liabilities assumed in acquisitions:    
Assets acquired in acquisition 20,103,661  
Liabilities assumed in acquisition 1,405,406  
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]    
Cash flows used in investing activities (net of effect of business combination):    
Purchase of Cord Use $ (10,500,000)